{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"Biogen defends anti-tau drug after stock slides on Alzheimer's readout","author_name":"techandbusiness.org · Tech & Business","thumbnail_url":"https://www.sharewise.com/rails/active_storage/blobs/proxy/eyJfcmFpbHMiOnsiZGF0YSI6NzIxMjMwNywicHVyIjoiYmxvYl9pZCJ9fQ==--05dadffab1eda6615d41732fbe206709fdb1e8d4/899.jpg?locale=us","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/zmthKiPWkZZt0t9mK5rKO7\" style=\"color:#fff;text-decoration:none;\">Biogen defends anti-tau drug after stock slides on Alzheimer's readout</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Biogen said yesterday that detailed data from the phase II CELIA study of its experimental tau-targeting Alzheimer's drug diranersen confirmed the trial did not meet its primary endpoint of demonstrat...</p>\n    </blockquote>"}